Add to ORKGPATENT: R. Vink, A.J.Nimmo. US 2005/0107380 A1 (PCT/AU01/00046) filed Jan 18, 2001; published Jan 11, 2005.A treatment for brain, spinal and nerve injury comprising use of a substance P receptor antagonist optionally in combination with a magnesium compound. There is also provided a formulation for use in this treatment comprising a substance P receptor antagonist and a magnesium compound.Invented by R. Vink, A.J.Nimmo; Hoffmann La-Roche agents for inventors
Abstract: The global pharmaceutical industry is facing unprecedented challenges that are increasingl...
© 2011 The Authors © 2011 The British Pharmacological SocietyMMB Ribeiro, M Pinto, M Heras, A Corre...
Substance P (SP) is a highly conserved member of the tachykinin peptide family that is widely expres...
This invention relates to a method of therapy of brain, spinal and nerve injury. There is also provi...
Copyright © 2002 Expert Opinion on Investigational DrugsIn industrialised countries, the mean per ca...
Methods for treating neurodegeneration and/or myelination in patients are disclosed comprising treat...
Patent for a topical remedy for the local treatment of rheumatism, neuralgia, paralysis and gout
[EN] The present application provides a combination product for the treatment and/or prevention of p...
Previous studies have demonstrated that the compound N-acetyl-L-tryptophan (NAT) reduces brain edema...
Copyright © 2004 Ashley PublicationsTraumatic brain injury (TBI) is one of the leading causes of dea...
Targeting analgesic drugs for spinal delivery reflects the fact that while the conscious experience ...
The present disclosure is directed to the use of fusogenic compounds such as polyethylene glycol (PE...
The neuropeptide substance P (SP) is a well-known mediator of neurogenic inflammation following a va...
The invention provides methods for treating conditions of the eye involving death or degeneration of...
The invention provides methods for treating conditions of the eye involving death or degeneration of...
Abstract: The global pharmaceutical industry is facing unprecedented challenges that are increasingl...
© 2011 The Authors © 2011 The British Pharmacological SocietyMMB Ribeiro, M Pinto, M Heras, A Corre...
Substance P (SP) is a highly conserved member of the tachykinin peptide family that is widely expres...
This invention relates to a method of therapy of brain, spinal and nerve injury. There is also provi...
Copyright © 2002 Expert Opinion on Investigational DrugsIn industrialised countries, the mean per ca...
Methods for treating neurodegeneration and/or myelination in patients are disclosed comprising treat...
Patent for a topical remedy for the local treatment of rheumatism, neuralgia, paralysis and gout
[EN] The present application provides a combination product for the treatment and/or prevention of p...
Previous studies have demonstrated that the compound N-acetyl-L-tryptophan (NAT) reduces brain edema...
Copyright © 2004 Ashley PublicationsTraumatic brain injury (TBI) is one of the leading causes of dea...
Targeting analgesic drugs for spinal delivery reflects the fact that while the conscious experience ...
The present disclosure is directed to the use of fusogenic compounds such as polyethylene glycol (PE...
The neuropeptide substance P (SP) is a well-known mediator of neurogenic inflammation following a va...
The invention provides methods for treating conditions of the eye involving death or degeneration of...
The invention provides methods for treating conditions of the eye involving death or degeneration of...
Abstract: The global pharmaceutical industry is facing unprecedented challenges that are increasingl...
© 2011 The Authors © 2011 The British Pharmacological SocietyMMB Ribeiro, M Pinto, M Heras, A Corre...
Substance P (SP) is a highly conserved member of the tachykinin peptide family that is widely expres...